A major breakthrough in the lung cancer therapy was marked by a pioneering phase 2 clinical study, known as Osimertinib study, in year 2015.The study, focused on the efficacy of osimertinib, a precision medicine, centered on patients with advanced NSCLC (NSCLC).Valuable insights into the treatment of this aggressive disease, as well as paved the way for further research and development in the field of oncology, were provided by the trial's findings.year 2015 Introduction to Osimertinib study Phase 2A key research, conducted in year 2015 as the Osimertinib study phase 2…
